Cencora, Inc. · NYSE (us_market)
Healthcare · Medical Distribution · United States
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2020-02-21$97.00 RISE2020-03-23$73.93 PEAK2020-06-08$102.30 108d | -23.8% 31d | Missed | Missed | — | — | +38.4% 77d | Missed |
Bath & Body Works reported lower first-quarter sales as the company overhauls its strategy in an attempt to return to growth.
Eva Boratto, who spent more than a decade at CVS in a variety of finance roles, will join the drug distributor later this summer, Cencora announced Wednesday.
Get this weekly dividend update on Champions, Contenders & Challengersâsee dividend changes, upcoming ex-dividend dates and pay dates.
Let's have a look at the S&P500 gap up and gap down stocks in today's session.
CONSHOHOCKEN, Pa., May 21, 2026--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company’s previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end of
Cencora, Inc. (NYSE:COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The letter emphasizes a long-term, fundamentals-driven investment philosophy, arguing that while stock prices can be volatile in the short run, they ultimately follow underlying earnings growth—illustrated through the “dog and owner” analogy. The […]
Latitude Investment Management, an investment management firm, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The letter emphasizes a long-term, fundamentals-driven investment philosophy, arguing that while stock prices can be volatile in the short run, they ultimately follow underlying earnings growth—illustrated through the “dog and owner” analogy. The […]
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Multiple law firms have launched investigations into Cencora (NYSE:COR) for potential securities law violations following its Q2 2026 results. The company reported revenue that missed prior estimates and reduced its revenue growth forecast, prompting the legal scrutiny. The investigations focus on whether Cencora and its management misled investors around the period of the reported results and updated outlook. Cencora, trading at $257.71 at the last close, is now under a spotlight that goes...
Multiple law firms have launched investigations into Cencora (NYSE:COR) for potential securities law violations following its Q2 2026 results. The company reported revenue that missed prior estimates and reduced its revenue growth forecast, prompting the legal scrutiny. The investigations focus on whether Cencora and its management misled investors around the period of the reported results and updated outlook. Cencora, trading at $257.71 at the last close, is now under a spotlight that goes...
Cencora’s first quarter results came in below Wall Street’s revenue expectations, and the market responded negatively. Management pointed to several factors behind the underperformance, including faster-than-expected brand-to-biosimilar conversions at a large mail order pharmacy customer, impacts from recent manufacturer price reductions, and lingering effects from the loss of certain customers. CEO Robert Mauch emphasized the resilience of Cencora’s business model, noting ongoing growth in spec
Cencora’s first quarter results came in below Wall Street’s revenue expectations, and the market responded negatively. Management pointed to several factors behind the underperformance, including faster-than-expected brand-to-biosimilar conversions at a large mail order pharmacy customer, impacts from recent manufacturer price reductions, and lingering effects from the loss of certain customers. CEO Robert Mauch emphasized the resilience of Cencora’s business model, noting ongoing growth in spec
Cencora, Inc. (NYSE:COR) is one of the 10 Best Depressed Stocks to Buy in 2026. On May 11, 2026, Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Cencora, Inc. (NYSE:COR) to $331 from $429 while maintaining an Overweight rating on the shares. The firm said the magnitude of the slowdown in U.S. […]
Cencora, Inc. (NYSE:COR) is one of the 10 Best Depressed Stocks to Buy in 2026. On May 11, 2026, Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Cencora, Inc. (NYSE:COR) to $331 from $429 while maintaining an Overweight rating on the shares. The firm said the magnitude of the slowdown in U.S. […]
CAH shares are down 9.4% YTD, but strong specialty drug growth, rising earnings estimates and a raised outlook may signal upside.
CAH shares are down 9.4% YTD, but strong specialty drug growth, rising earnings estimates and a raised outlook may signal upside.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| COR | -11.39% | -27.72% | -20.25% | -7.51% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -14.36% | -22.00% | -16.81% | -20.20% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 9.19M | $2.89B | 0.10% | Trimmed-1.2% | 2026-03-31 |
| FidelityFMR | fundamental | 6.69M | $2.10B | 0.11% | Added+22.5% | 2026-03-31 |
| Wellington | fundamental | 4.55M | $1.43B | 0.27% | Unchanged | 2026-03-31 |
| CapResearch | fundamental | 1.96M | $615.60M | 0.10% | Trimmed-28.7% | 2026-03-31 |
| Citadel | multi-strat | 394.3K | $123.88M | 0.16% | Added+122.7% | 2026-03-31 |
| DEShaw | quant | 95.5K | $29.99M | 0.02% | Trimmed-73.4% | 2026-03-31 |
| TwoSigma | quant | 23.1K | $7.24M | 0.01% | Trimmed-59.8% | 2026-03-31 |
| Bridgewater | macro | 14.2K | $4.47M | 0.02% | Trimmed-43.5% | 2026-03-31 |
| TRowePrice | fundamental | 7.32M | $2.30M | 0.27% | Added+4.7% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-28 | DURCAN DERMOT MARK | Director | P Open-market purchase | 4,000 | $266.26 | +$1.07M |
| 2026-05-05 | NALLY DENNIS M | Director | A Grant / award | 116 | $304.00 | +$35.3K |
| 2026-05-05 | Cooper Ellen | Director | A Grant / award | 99 | $304.00 | +$30.1K |
| 2026-05-05 | Tyler Lauren M | Director | A Grant / award | 99 | $304.00 | +$30.1K |
| 2026-04-02 | Krikorian Lazarus | SVP & Chief Accounting Officer | A Grant / award(deriv) | 3,936 | — | +$0 |
| 2026-03-13 | Cleary James F | Chief Financial Officer | M Option exercise(deriv) | 12,623 | — | +$0 |
| 2026-03-13 | Cleary James F | Chief Financial Officer | F Tax withholding | 5,409 | $350.30 | −$1.89M |
| 2026-03-13 | Cleary James F | Chief Financial Officer | M Option exercise | 12,623 | — | +$0 |
| 2026-03-13 | Campbell Elizabeth S | Executive Vice President | M Option exercise(deriv) | 12,623 | — | +$0 |
| 2026-03-13 | Campbell Elizabeth S | Executive Vice President | F Tax withholding | 5,842 | $350.30 | −$2.05M |
| 2026-03-13 | Campbell Elizabeth S | Executive Vice President | M Option exercise | 12,623 | — | +$0 |
| 2026-03-13 | Battaglia Silvana | Executive Vice President | M Option exercise(deriv) | 8,415 | — | +$0 |
| 2026-03-13 | Battaglia Silvana | Executive Vice President | F Tax withholding | 3,673 | $350.30 | −$1.29M |
| 2026-03-13 | Battaglia Silvana | Executive Vice President | M Option exercise | 8,415 | — | +$0 |
| 2026-03-09 | Ryerkerk Lori | Director | A Grant / award | 557 | $359.28 | +$200.1K |
| 2026-03-09 | Miller Redonda | Director | A Grant / award | 557 | $359.28 | +$200.1K |
| 2026-03-09 | Kim Lorence H. | Director | A Grant / award | 557 | $359.28 | +$200.1K |
| 2026-03-09 | GREENBERG LON R | Director | A Grant / award | 557 | $359.28 | +$200.1K |
| 2026-03-09 | DURCAN DERMOT MARK | Director | A Grant / award | 905 | $359.28 | +$325.1K |
| 2026-03-09 | Clyburn Frank | Director | A Grant / award | 557 | $359.28 | +$200.1K |
| 2026-03-09 | Baumann Werner | Director | A Grant / award | 557 | $359.28 | +$200.1K |
| 2026-03-09 | Tyler Lauren M | Director | A Grant / award | 557 | $359.28 | +$200.1K |
| 2026-03-09 | Tyler Lauren M | Director | A Grant / award | 84 | $359.22 | +$30.2K |
| 2026-03-09 | NALLY DENNIS M | Director | A Grant / award | 557 | $359.28 | +$200.1K |
| 2026-03-09 | NALLY DENNIS M | Director | A Grant / award | 98 | $359.22 | +$35.2K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 4.37 | — | — |
| 2026-05-06 | 4.73 | 4.75 | +0.48% |
| 2026-02-04 | 4.04 | 4.08 | +0.99% |
| 2025-11-05 | 3.79 | 3.84 | +1.44% |
| 2025-08-06 | 3.84 | 4.00 | +4.24% |
| 2025-05-07 | 4.10 | 4.42 | +7.92% |
| 2025-02-05 | 3.52 | 3.73 | +5.96% |
| 2024-11-06 | 3.23 | 3.34 | +3.47% |
| 2024-07-31 | 3.22 | 3.34 | +3.75% |
| 2024-05-01 | 3.69 | 3.80 | +2.89% |
| 2024-01-31 | 2.89 | 3.28 | +13.46% |
| 2023-11-02 | 2.81 | 2.86 | +1.92% |
| 2023-08-02 | 2.83 | 2.92 | +3.35% |
| 2023-05-02 | 3.30 | 3.50 | +6.09% |
| 2023-02-01 | 2.63 | 2.71 | +2.91% |
| 2022-11-03 | 2.57 | 2.60 | +1.03% |